Keywords: Influenza; Vaccination rate; Predictors; Inflammatory rheumatic disease; CI; Confidence Interval; DMARD; disease-modifying antirheumatic drug; EULAR; The European League against Rheumatism; GP; General Practitioner; HIV; Human Immunodeficiency Virus; IVR;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Biologic therapies; co-morbidities; DMARD; MRCP; rheumatoid arthritis; treat-to-target;
Keywords: Rheumatoid arthritis; Inflammation; Methotrexate; Prodrug; Thiazolidinone; Reactive oxygen species; ADMET; absorption, distribution, metabolism, excretion, toxicity; CFA; Complete Freund's Adjuvant; CIA; collagen-induced arthritis; CL'int; apparent intrin
Keywords: ACPA; anti-citrullinated protein antibody; AP; recombinant human placental alkaline phosphatase = hRESCAP® (human rescue alkaline phosphatase); DAS; disease activity score; DMARD; disease modifying anti-rheumatic drug; EULAR; European league against rheu
Keywords: RA; rheumatoid arthritis; TCZ; tocilizumab; TOFA; tofacitinib citrate; MTX; methotrexate; DMARD; disease-modifying antirheumatic drug; bDMARD; biologic disease-modifying antirheumatic drug; nbDMARD; non-biologic disease-modifying antirheumatic drug; obDMA
Keywords: rheumatoid arthritis; DMARD; periprosthetic joint infection; total joint arthroplasty; systematic review;
Keywords: Dementia; Inflammation; Rheumatoid arthritis; Biologic; DMARD;
Keywords: Rheumatoid arthritis; Serious infection; Mannose binding lectin; Immune system; Risk factor; bDMARD; Biologic disease-modifying antirheumatic drug; COPD; Chronic obstructive pulmonary disease; CS; Corticosteroids; DMARD; Disease-modifying antirheumatic dr
Keywords: ACR; American College of Rheumatology; ALT; alanine aminotransferase; ANA; anti-nuclear antibodies; anti-CCP; anti-cyclic citrullinated antibodies; anti-TG; anti-thyroglobulin antibody; AST; aspartate aminotransferase; bDMARD; biologic disease modifying a
Keywords: ACR; American College of Rheumatology; ACPA; anti-citrullinated peptide antibodies; CI; confidence interval; CRP; C-reactive protein; DAS; disease activity score; DMARD; disease modifying anti-rheumatic drug; ESR; erythrocyte sedimentation rate; EULAR; Eu
Keywords: Methotrexate; Chloroquine; Hydroxychloroquine; DMARD; Rheumatoid arthritis
Keywords: CAD; coronary artery disease; CNS; central nervous system; DMARD; disease-modifying antirheumatic drug; HR; hazard ratio; ICD-9-CM; International Classification of Disease, Ninth Revision, Clinical Modification; NHIRD; National Health Insurance Research D
Keywords: Biologic agents; adverse effect; infection; autoimmunity; paradoxical inflammation; ANA; Antinuclear antibody; AS; Ankylosing spondylitis; DMARD; Disease-modifying antirheumatic drug; IBD; Inflammatory bowel disease; ILD; Interstitial lung disease; NTM; N
Keywords: DMARD; Anti-TNF; Pregnancy; Lactation; Rheumatic diseases; Autoimmune diseases;
Keywords: AE; adverse event; ACR; American College of Rheumatology; Apo; apolipoprotein; BID; twice daily; BP; blood pressure; CHF; congestive heart failure; CRP; C-reactive protein; csDMARD; conventional synthetic disease-modifying antirheumatic drug; CV; cardiova
Keywords: ABA; abatacept; ADA; adalimumab; AIx; augmentation index; AMI; acute myocardial infarction; ANA; anakinra; Apo; apolipoprotein; AS; ankylosing spondylitis; CTZ; certolizumab pegol; CV; cardiovascular; CVD; cardiovascular disease; DMARD; disease-modifying
Keywords: BA; biological agents; DMARD; disease-modifying antirheumatoid drugs; RA; rheumatoid arthritis; Rheumatoid arthritis; Neurological manifestations; Peripheral neuropathy; Cervical spine; Brain;
Keywords: DMARD; disease-modifying antirheumatic drug; ICD-9-CM; International Classification of Diseases, Ninth Revision, Clinical Modification; IPTW; inverse probability treatment weight; MCO; managed care organization; PS; propensity score; VSD; Vaccine Safety D
Keywords: ACPA; anti-citrullinated protein antibodies; Anti-CarP; anti-carbamylated protein; CASPAR; Classification of psoriatic arthritis; CCP; cyclic citrullinated protein; DAS; Disease activity score; DMARD; disease modifying anti-rheumatic drug; FDA; US Food an
Keywords: ACPA; anticitrullinated protein antibody; CCP; cyclic citrullinated peptide; CTD; connective tissue disease; CXCL; CXC chemokine ligand; Dlco; diffusing capacity of lung for carbon monoxide; DMARD; disease-modifying antirheumatic drug; HRCT; high resoluti
Keywords: Juvenile idiopathic arthritis; DMARD; TNF-α inhibitors; Biologic; Treatment strategy
Keywords: Atherosclerosis; Rheumatoid arthritis; DMARD; TNFα; Cardiovascular risk factor;
Monounsaturated fatty acids might be key factors in the Mediterranean diet that suppress rheumatoid arthritis disease activity: The TOMORROW study
Keywords: Inflammation; Diet therapy; Rheumatoid arthritis; Disease activity; Nutrition; Mediterranean diet; BDHQ; brief self-administered diet history questionnaire; bDMARD; biological disease-modifying antirheumatic drugs; C; control; csDMARDs; conventional synth
Epitope-based ligation of ICAM-1: Therapeutic target for protection against the development of rheumatoid arthritis
Keywords: MD-3; Anti-ICAM-1antibody; Antigen-specific; Collagen-induced arthritis; In situ induction; RA; rheumatoid arthritis; CMV; cytomegalovirus; DMARD; disease-modifying anti-rheumatic drug; DC; dendritic cell; mAb; monoclonal antibody; CIA; collagen-induced a
Comorbidity of Type 1 Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis
Keywords: JIA; type 1 diabetes mellitus prevalence; autoimmune diseases; DMARDs; observational study; AID; Autoimmune disease; AIT; Autoimmune thyroiditis; bDMARD; Biological DMARD; BMI; Body mass index; CD; Celiac disease; cJADAS; Clinical Juvenile Arthritis Disea
Leptin in autoimmune mechanisms of systemic rheumatic diseases
Keywords: Leptin; Connective tissue diseases; Adipokines; Inflammatory arthritis; Vasculitis; WAT; white adipose tissue; IL; interleukin; BMI; body mass index; PPAR; peroxisome proliferator-activated receptor; JAK; janus kinases; STAT; signal transducers and activa
Methods for segmentation of rheumatoid arthritis bone erosions in high-resolution peripheral quantitative computed tomography (HR-pQCT)
Keywords: RA; rheumatoid arthritis; ACPA; anti-cyclic citrullinated peptide antibody; HR-pQCT; high-resolution peripheral quantitative computed tomography; MCP; metacarpophalangeal; mESE; modified Evaluation Script for Erosions; MIAF; Medical Image Analysis Framewo
Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases
Keywords: AS; ankylosing spondylitis; BASDAI; Bath Ankylosing Spondylitis Disease Activity Index; CMR; cardiovascular magnetic resonance; CRP; C-reactive protein; DMARD; disease modifying antirheumatic drug; DAS28CRP; disease activity score with 28 tender and swoll
Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine
Keywords: Methotrexate; Rheumatoid arthritis; Circulating B cells; Pneumococcal vaccination; Antibody responses; RA; rheumatoid arthritis; MTX; methotrexate; DMARD; disease modifying -rheumatic drug; Ig; immunoglobulin; ELISA; enzyme-linked immunosorbent assay; ELS
Naturally occurring xanthone and benzophenone derivatives exert significant anti-proliferative and proapoptotic effects in vitro on synovial fibroblasts and macrophages from rheumatoid arthritis patients
Keywords: DMARD; disease-modifying anti-rheumatic drug; DMSO; dimethylsulfoxide; FLS; fibroblast-like synoviocytes; IG; iriflophenone 3-C-glucoside; IM; isomangiferin; M; mangiferin; MC; maclurin; NM; neomangiferin; NSAIDs; non-steroidal anti-inflammatory drugs; NT
Modulatory effect of standardised amentoflavone isolated from Juniperus communis L. agianst Freund's adjuvant induced arthritis in rats (histopathological and X Ray anaysis)
Keywords: MTX; methotrexate; MEJC; methanolic extract of Juniperus commun; AF; amentoflavone; MSD; muscoskeletal disorder; DMARD; disease modifying anti-rheumatic drug; CFA; myobacterium tuberculosis; Freund's adjuvant induced arthritis; Amentoflavone; Juniperus
Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy
Keywords: ACPA; anti-citrullinated protein antibody; B10; IL-10 producing regulatory B cells; Bregs; regulatory B cells; CCP; cyclic citrullinated peptide specific antibody; CRP; C reactive protein; DAS; disease activity score; DMARD; disease-modifying anti-rheumat
Adult onset Still's disease associated with malignancy-Cause or coincidence?
Keywords: ALAT; alanine aminotransferase; ANA; antinuclear antibodies; AOSD; adult onset Still's disease; ASAT; asparatate aminotransferase; CRP; C-reactive protein; DMARD; disease modifying antirheumatic drugs; ESR; erythrocyte sedimentation rate; IL; interleuki
Ingested (oral) rituximab inhibits EAE
Keywords: ACTH; adrenocorticotropin hormone; α-MSH; alpha-melanocyte stimulating hormone; EAE; experimental autoimmune encephalomyelitis; DMARD; disease modifying anti-rheumatic drugs; GALT; gut associated lymphoid tissue; RTX; rituximab; SIRS; soluble immune resp
IL-1 receptor antagonist (IL-1Ra)-Fc ameliorate autoimmune arthritis by regulation of the Th17 cells/Treg balance and arthrogenic cytokine activation
Keywords: ACR; American College of Rheumatology; APC; allophycocyanin; CD; cluster of differentiation; CIA; collagen induced arthritis; CII; type II collagen; CTLA-4; cytotoxic T-lymphocyte antigen 4; DMARD; disease-modifying antirheumatic drug; ELISA; enzyme-linke
Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data
Keywords: TCZ; tocilizumab; IL-6; interleukin 6; DMARD; disease-modifying antirheumatic drugs; RA; rheumatoid arthritis; TNF; tumor necrosis factor; MTX; methotrexate; LMP; last menstrual period; ETOP; elective termination of pregnancy; Tocilizumab; Rheumatoid arth
Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy
Keywords: Ab; antibody; ACL; anterior cruciate ligament; ADAMTS-4; a disintegrin and metalloproteinase with thrombospondin motifs 4; ADAMTS-5; a disintegrin and metalloproteinase with thrombospondin motifs 5; AGE; advanced glycation end product; AIA; antigen induce
Pregnancy outcomes following exposure to abatacept during pregnancy
Keywords: Pregnancy; Abatacept; Exposure; Congenital anomalies; Biological disease-modifying antirheumatic drugs; DMARD; disease-modifying antirheumatic drug; FDA; Food and Drug Administration; MADCF; Metropolitan Atlanta Congenital Defects Program; MMF; mycophenol
Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain - Interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis
Keywords: HRV; heart rate variability; RA; rheumatoid arthritis; FM; fibromyalgia; CSF; cerebrospinal fluid; IL; interleukin; IL-1Ra; interleukin 1 receptor antagonist; TNF; tumor necrosis factor; CCL-2; chemokine (C-C motif) ligand 2; BDNF; brain-derived neurotr
CD45RA-Foxp3high activated/effector regulatory T cells in the CCR7Â +Â CD45RA-CD27Â +Â CD28Â +Â central memory subset are decreased in peripheral blood from patients with rheumatoid arthritis
Keywords: TCM; central memory T cells; TEM; effector memory T cells; RA; rheumatoid arthritis; Treg; regulatory T cells; CTLA4; cytotoxic T-lymphocyte antigen 4; Foxp3; forkhead box P3; PerCPCy5.5; peridin chlorophyll protein-cyanin 5.5; ECD; energy-coupled dye; DA
Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response
Keywords: LDL; low density lipoprotein; Tregs; regulatory T cells; IL; interleukin; TGF-β; transforming growth factor beta; Foxp3; forkhead box 3; IL-2R; interleukin-2 receptor; CTLA-4; cytotoxic T-lymphocyte antigen 4; NK; natural killer; DCs; dendritic cells; TC
What is the best treatment strategy for early RA?
Keywords: Rheumatoid arthritis; DMARD; Glucocorticoid; Combination strategy; Tight control; Treat to target; Remission
Is there a place for initial treatment with biological DMARDs in the early phase of RA?
Keywords: Rheumatoid arthritis; Biologic; DMARD; Remission; Induction
Biosimilar DMARD in rheumatology: A general perspective with focus on India
Keywords: Biologic; Biosimilar; DMARD; Rheumatoid arthritis;
Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine
Keywords: 4EBP1; eukaryotic translation initiation factor 4E binding protein 1; ADRA1D; adrenergic α-1D-receptor; AE; adverse events; ACE; angiotensin I converting enzyme (peptidyl-dipeptidase A) 1; SD; Sprague-Dawley; DAG; diacylglycerol; DMARD; disease modifying
Disyuntivas en el tratamiento de la artritis reumatoide: razones para el uso de abatacept
Keywords: Artritis reumatoide; Criterios de clasificación; FAME; Tratamientos biológicos; AbataceptRheumatoid arthritis; Classification criteria; DMARD; Biologics; Abatacept
Healthcare Utilization and Comorbidity Burden among Children and Young Adults in the United States with Systemic Lupus Erythematosus or Inflammatory Bowel Disease
Keywords: DMARD; Disease-modifying antirheumatic drug; IBD; Inflammatory bowel disease; ICD-9-CM; International Classification of Diseases, 9th Revision-Clinical Modification; SLE; Systemic lupus erythematosus;
My Treatment Approach to Rheumatoid Arthritis
Keywords: ACPA; anti-citrullinated protein antibody; ACR; American College of Rheumatology; BeSt; Behandel-Strategieën [trial]; CDAI; Clinical Disease Activity Index; CRP; C-reactive protein; CTLA-4:Ig; cytotoxic T lymphocyte-associated antigen 4:immunoglobuli
Initial Management of Rheumatoid Arthritis
Keywords: Rheumatoid arthritis; Disease-modifying antirheumatic drug; DMARD;
Power of crowdsourcing: Novel methods of data collection in psoriasis and psoriatic arthritis
Keywords: crowdsource; crowdsourcing; data collection; psoriasis; psoriatic arthritis; treatment; ACR-20; at least 20% improvement in symptoms based on American College of Rheumatology (ACR) criteria; ACR-50; at least 50% improvement in symptoms based on ACR criter